share_log
  • Headlines
  • Sanofi agrees to acquire Denavir Pharmaceuticals for $2.2 billion, causing the latter's shares to surge nearly 39%.
focus on technology stocks
Topic 36896 Subscribers

Sanofi agrees to acquire Denavir Pharmaceuticals for $2.2 billion, causing the latter's shares to surge nearly 39%.

Zhitong Finance ·  Dec 24 22:48

$Dynavax Technologies (DVAX.US)$ Surging nearly 39%. In terms of news, $Sanofi (SNY.US)$ Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion in a bid to expand its current vaccine portfolio centered on the flu vaccine business. According to a statement released by Sanofi on Wednesday, it will acquire Dynavax Technologies, headquartered in Emeryville, California, USA, at a cash price of $15.50 per share. This offer represents a 39% premium over Dynavax Technologies' closing price on Tuesday.

Through this acquisition, the French pharmaceutical giant will gain access to an already marketed hepatitis B vaccine in the United States, as well as an experimental shingles vaccine currently in early-stage human trials. Sanofi stated that this move will strengthen its market positioning in the adult vaccination field. Currently, Sanofi's vaccine portfolio covers multiple indications, including influenza, respiratory syncytial virus, meningitis, and pertussis.

Editor/Doris

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Airstar Bank. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.